  Background: Beta-amyloid (A$\beta$) plaques and tau protein tangles in the
brain are the defining 'A' and 'T' hallmarks of Alzheimer's disease (AD), and
together with structural atrophy detectable on brain magnetic resonance imaging
(MRI) scans as one of the neurodegenerative ('N') biomarkers comprise the ''ATN
framework'' of AD. Current methods to detect A$\beta$/tau pathology include
cerebrospinal fluid (CSF; invasive), positron emission tomography (PET; costly
and not widely available), and blood-based biomarkers (BBBM; promising but
mainly still in development).
  Objective: To develop a non-invasive and widely available structural
MRI-based framework to quantitatively predict the amyloid and tau measurements.
  Methods: With MRI-based hippocampal multivariate morphometry statistics (MMS)
features, we apply our Patch Analysis-based Surface Correntropy-induced Sparse
coding and max-pooling (PASCS-MP) method combined with the ridge regression
model to individual amyloid/tau measure prediction.
  Results: We evaluate our framework on amyloid PET/MRI and tau PET/MRI
datasets from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Each
subject has one pair consisting of a PET image and MRI scan, collected at about
the same time. Experimental results suggest that amyloid/tau measurements
predicted with our PASCP-MP representations are closer to the real values than
the measures derived from other approaches, such as hippocampal surface area,
volume, and shape morphometry features based on spherical harmonics (SPHARM).
  Conclusion: The MMS-based PASCP-MP is an efficient tool that can bridge
hippocampal atrophy with amyloid and tau pathology and thus help assess disease
burden, progression, and treatment effects.
